Identifying the optimal donor for natural killer cell adoptive therapy to treat paediatric B- and T-cell acute lymphoblastic leukaemia. by Foley, Bree et al.
ORIGINAL ARTICLE
Identifying the optimal donor for natural killer cell
adoptive therapy to treat paediatric B- and T-cell acute
lymphoblastic leukaemia
Bree Foley1, Clara Ta1, Samantha Barnes1, EmmadeJong1, Michelle Nguyen1,2, Laurence C Cheung1,3,
Anthony Buzzai1, Teagan Wagner1, Ben Wylie1, Sonia Fernandez2, Mark Cruickshank2,
Raelene Endersby1, Ursula Kees1 & Jason Waithman1
1Telethon Kids Institute, University of Western Australia, Nedlands, Australia
2School of Biomedical Sciences, University of Western Australia, Nedlands, Australia
3School of Pharmacy and Biomedical Sciences, Curtin University, Perth, Australia
Correspondence
Dr J Waithman, Telethon Kids Institute,
The University of Western Australia,
Northern Entrance, Perth Children’s Hospital,
15 Hospital Avenue, Nedlands, PO Box 855,
West Perth, WA 6872, Australia.
E-mail: jason.waithman@telethonkids.org.au
Received 7 January 2020;
Revised 10 June 2020;
Accepted 10 June 2020
doi: 10.1002/cti2.1151
Clinical & Translational Immunology
2020; 9: e1151
Abstract
Objectives. Natural killer (NK) cells are an attractive source of cells
for an ‘off the shelf’ cellular therapy because of their innate
capacity to target malignant cells, and ability to be transferred
between donors and patients. However, since not all NK cells are
equally effective at targeting cancer, selecting the right donor for
cellular therapy is critical for the success of the treatment. Recently,
cellular therapies utilising NK cells from cytomegalovirus (CMV)-
seropositive donors have been explored. However, whether these
NK cells are the best source to treat paediatric acute lymphoblastic
leukaemia (ALL) remains unclear. Methods. Using a panel of
patient-derived paediatric B- and T-ALL, we assessed the ability of
NK cells from 49 healthy donors to mount an effective functional
response against these two major subtypes of ALL. Results. From
this cohort, we have identified a pool of donors with superior
activity against multiple ALL cells. While these donors were more
likely to be CMV+, we identified multiple CMVneg donors within
this group. Furthermore, NK cells from these donors recognised B-
and T-ALL through different activating receptors. Dividing
functional NK cells into 29 unique subsets, we observed that within
each individual the same NK cell subsets dominated across all ALL
cells. Intriguingly, this occurred despite the ALL cells in our panel
expressing different combinations of NK cell ligands. Finally, we
can demonstrate that cellular therapy products derived from these
superior donors significantly delayed leukaemia progression in
preclinical models of ALL. Conclusions. We have identified a pool
of superior donors that are effective against a range of ALL cells,
representing a potential pool of donors that can be used as an
adoptive NK cell therapy to treat paediatric ALL.
Keywords: acute lymphoblastic leukaemia, cellular therapy,
cytomegalovirus, natural killer cells
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INTRODUCTION
Natural killer (NK) cells have the capacity to target
transformed and malignant cells. Early studies
utilising autologous NK cells as an
immunotherapy showed limited clinical efficacy1–3
which was attributed to a family of inhibitory
receptors known as the killer immunoglobulin-like
receptors (KIRs) that recognise allelic epitopes
present on certain HLA-A, HLA-B and HLA-C
molecules.4,5 Inhibitory KIR prevents NK cell
elimination of cancer cells upon recognition of
self-HLA.4 To overcome NK cell inhibition,
subsequent studies explored the use of allogeneic
NK cells, pairing donors and recipients with a
mismatch between at least one KIR gene in the
donor and HLA class I allele (KIR ligand), in the
context of either haematopoietic stem cell
transplantation (HSCT)6 or adoptive transfer of NK
cells directly.7 Significant survival benefits
following NK cell immunotherapy have been
observed for acute myeloid leukaemia (AML) and
paediatric patients with acute lymphoblastic
leukaemia (ALL).6,8–10 However, while these
approaches work for some ALL patients, strategies
to further enhance NK cell immunotherapies are
warranted.
One strategy to improve adoptive NK cell
therapy is to identify those NK cells most effective
at eliminating cancer. We, and others, have
identified that following cytomegalovirus (CMV)
infection, unique subsets of NK cells expand that
differ in their capacity to proliferate, survive,
eliminate tumor cells, secrete cytokines, and
mediate antibody-dependent responses.11–17
Commonly termed adaptive NK cells, they
typically express the activating receptor NKG2C,
CD57 and an inhibitory KIR for self-HLA.18
Furthermore, NKG2C+ NK cells undergo epigenetic
reprogramming of the IFNG locus following CMV
infection, resulting in their ability to rapidly
produce IFNc once activated at a faster rate than
na€ıve NK cells.19 Clinically, both CMV
reactivation20 and expansion of NKG2C+ NK
cells21,22 have been associated with reduced risk
of leukaemic relapse following HSCT. Recently,
the use of these adaptive NK cells as the source of
cells for preclinical NK cell adoptive therapy has
demonstrated promising results across a range of
cancers including ALL23,24 and phase I clinical trials
are currently underway to use NKG2C+CD57+
adaptive NK cells from CMV-seropositive (CMV+)
donors to treat AML and solid tumors
(NCT03081780; NCT03319459).
Although these findings are extremely
encouraging, it is not clear whether NK cells from
CMV+ donors are the most effective NK cell subset
against ALL. In this study, we examined the
capacity of NK cells from 49 healthy donors to
mount effective functional responses against a
panel of patient-derived paediatric B- and T-ALL
cells, which represent the major subtypes of
childhood leukaemia. We identified a group of
donors who exhibited superior responses against
multiple ALL cells, representing a potential pool
of donors that could be used to develop an
adoptive NK cell therapy capable of treating a
range of ALL subtypes. The pool of superior
donors comprised CMV+ and CMVneg individuals,
each of whom harboured discrete NK cell subsets
that dominated against both B-and T-ALL despite
variation in the HLA type expressed on the target
ALL cells. Finally, adoptive transfer of NK cells
from our superior donors was associated with
improved survival in preclinical models of B- and
T-ALL.
RESULTS
Highly effective NK cells against both B- and
T-ALL identified in CMV+ and CMVneg donors
We sought to identify whether NK cells from
CMV+ donors have enhanced capacity to target
the two major types of paediatric ALL: B- and T-
ALL. We examined the capacity of resting NK cells
from 49 healthy donors (CMV+ n = 32, CMVneg
n = 17; Supplementary table 1) to degranulate
(CD107a expression) or produce cytokines (TNFa)
following co-culture with a panel of patient-
derived leukaemic cells (Table 1). Overall, all ALL
cells stimulated an effective response resulting in
increased CD107a expression (Figure 1a) and TNFa
production (Figure 1b). Between CMV+ and
CMVneg donors, there was no significant
difference in the proportion of cells exhibiting
increased CD107a expression or TNFa production
across the ALL cells. However, the range of
responses between CMV+ donors was greater than
that of CMVneg donors. As not all CMV+ donors
expand adaptive NK cells with enhanced effector
function potential,16 we were interested in
whether an increased proportion of these cells
correlated with enhanced function against ALL.
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While the phenotype of adaptive NK cells can
vary amongst individuals,14,16 we focused our
analysis on the broad adaptive NK cell subset,
NKG2C+CD57+ NK cells and their ability to
produce TNFa. Similar to previous reports,16 we
observe hat about 1/3 of our CMV+ donors have
expanded NKG2C+CD57+ NK cells (Supplementary
figure 1). Intriguingly, expansion of NKG2C+CD57+
NK cells correlated with enhanced TNFa
production against all B-ALL cells (r-value > 0.5,
P < 0.05), but only 1 T-ALL, MOLT-4 (Figure 1c). To
further confirm this, we divided CD56+ NK cells
into 4 groups: NKG2C+CD57neg, NKG2C+CD57+,
NKG2CnegCD57+ and NKG2CnegCD57neg and
assessed the ability of each of these subsets to
produce TNFa against our panel of ALL cells
(Figure 1d). Of the four subsets, NKG2C+CD57+ NK
cells were the most effective against B-ALL, but
this was not true for T-ALL. Collectively, these
results demonstrate that although adaptive NK
cells are effective against B-ALL, they may not be
the most effective NK cells across all types of ALL.
Identification of superior donors against
both B- and T-ALL
Next, we sought to determine whether donors
with high responses against one ALL cell were
responders against other ALL cells, given the
degree of variation in responses observed in our
initial screen. Unsupervised hierarchical clustering
based on the percentage of CD56+ NK cells
expressing CD107a (Figure 2a) or producing TNFa
(Figure 2b) revealed clustering of donors with
similar responses against the 9 ALL cells. For
CD107a, there was a cluster of 9 donors who all
exhibited high responses against at least 6 of the
different ALL cells (both B- and T-ALL). A similar
cluster of 12 donors was observed for TNFa
production, with moderate to high responses
against the majority of ALL cells. These donors
also had high responses against the class I-
negative cell line, K562 (data not shown).
Importantly, not all of these high-performing
donors were CMV+. In contrast, there was a small
pool of donors who solely had strong activity
against one leukaemic cell line, PER-145, yet this
was only for CD107a as there was little TNFa
produced by these donors. Furthermore, there
were clusters of donors who had weak responses
against most of the ALL cells accounting for about
1/4–1/3 of donors.
NK cells from superior donors differ in their
recognition of B-ALL and T-ALL
NK cell recognition of paediatric ALL has
previously been reported to occur through the
activating receptors DNAM-1 and NKG2D.9,25 We
therefore examined the use of these receptors in
the recognition of ALL by superior NK cells (a
combination of donors identified in Figure 2;
PB014, PB012, PB011, PB016, PB005, PB035, PB036
and PB041). Using gene-expression data, we
observed similar levels of the NKG2D ligands:
MICA, MICB, ULBP1 and ULBP2, and the DNAM-1
ligands: CD112 and CD155 across all cells in our
panel (Figure 3a). Blocking NKG2D on our
superior NK cells significantly decreased both
CD107a expression and TNFa production against
each T-ALL cell, whereas blocking DNAM-1 only
had an effect against PER-117 (Figure 3b). While
blocking NKG2D had some effect on B-ALL with
significant decreases in CD107a and TNFa against
PER-371 and PER-377, this was not as pronounced
as T-ALL. Because of these discrepant results, we
Table 1. HLA class I typing of ALL cells
Cell line ALL HLA-A HLA-B HLA-C KIR ligandsa
PER-371 B-ALL 0301, 2902 3801, 5701 0602, 1203 C1 C2 Bw4
PER-377 B-ALL 0301 3501, 4501 0401, 0602 C2
PER-145 B-ALL 0101, 2402 3502, 3701 0402 ,0602 C2 Bw4
PER-278 B-ALL 0201, 3201 2705, 4402 0202, 0501 C2 Bw4
JURKAT T-ALL 0301 07, 35 0401, 0702 C1 C2
MOLT-4 T-ALL 0101, 2501 1801, 5801 0602, 1203 C1 C2 Bw4
CEM T-ALL 03, 31 08, 40 0304, 0701 C1
PER-255 T-ALL 0101, 3101 0801, 4001 0304, 0701 C1
PER-117 T-ALL 0101, 3001 0801, 1302 0602, 0701 C1 C2 Bw4
a
KIR ligands determined by the presence of the C1 and C2 epitopes for HLA-C and the Bw4 epitope for HLA-A and HLA-B.
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next assessed the surface expression of a subset of
NKG2D (MICA/B) and DNAM-1 (CD112 and CD155)
ligands (Figure 3c). Despite similar mRNA
expression, surface expression differed greatly
amongst the ALL cells. Overall B-ALL cells
expressed slightly lower levels of MICA/B which
may partly explain the difference in NKG2D
binding. Interestingly, while most ALL cells
Figure 1. NK cells from CMV+ and CMVneg donors are effective against B- and T-ALL with adaptive NK cells from CMV+ donors better against B-
ALL. Donors were divided into two groups CMV+ (n = 32) and CMV (n = 17) prior to incubation with either media alone (data not shown) or
against a panel of leukaemic cell targets. After incubation, CD107a expression (a) and TNFa production (b) were measured on CD56+ CD3 NK
cells. (c) The percentage of NK cells expressing NKG2C and CD57 from CMV+ donors was correlated with the percentage of CD56+ NK cells
producing TNFa. Pearson’s r and the P-value for each pair were calculated. (d) CD56+ NK cells from CMV+ donors were divided into four groups:
NKG2C+CD57neg, NKG2C+CD57+, NKG2CnegCD57+ and NKG2CnegCD57neg. TNFa production was measured after 5 h of incubation with
leukaemic cell targets. Bars represent the means  SEM. NKG2C+CD57+ NK cells were compared to the other subsets using the paired Student’s
t-test, *P ≤ 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.001.
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expressed similar levels of CD112 and CD155, only
PER-117 expressed very high levels of CD155 and
was the only ALL cell to respond to blocking
DNAM-1. Taken together, these results suggest
that additional receptors are involved in the
recognition of B-ALL, and thus, we investigated
additional activating receptors including NKG2C,
NKp30, NKp46 and 2B4. Of these additional
receptors, only 2B4 appeared to play a role in NK
cell recognition, as blocking 2B4 significantly
decreased both CD107a expression and TNFa
production against two of the B-ALL cells, PER-371
and PER-278 (Figure 3d). Despite PER-377 also
expressing equivalent levels of CD48, the ligand
for 2B4 (Supplementary figure 2a) there was no
effect of blocking 2B4. Similarly, blocking NKp30,
NKp46 or HLA-E (ligand for NKG2C) failed to
suppress NK cell function (Supplementary figure
2b and c). Collectively, this demonstrates that our
superior donors recognise B- and T-ALL through
distinct mechanisms.
CD57 expression demarcates NK cell subsets
with enhanced effector function against
both B- and T-ALL
We next sought to determine whether there were
differences in the phenotype of the NK cell subset
(s) that had the highest effector function against
each of the ALL cells. CD107a+ or TNFa+ NK cells
from the top 20 donors against each ALL cell were
divided into 29 unique subsets based on CD158a,
CD158b, KIR3DL1, NKG2C and CD57 expression
(Figure 4 CD107a, Supplementary figure 3 TNFa).
While there was a large range in responses, the
most functional NK cells all expressed CD57,
suggesting that NK cells expressing CD57 are the
most effective against paediatric B- and T-ALL.
Figure 2. A cluster of donors dominate against several ALL cells. Unsupervised hierarchical clustering analysis based on the percentage of CD56+
NK cells expressing CD107a (a) or producing TNFa (b). This analysis clustered donors (indicated by PB number) based on their similar responses
against the 9 ALL cells. The cluster of donors with the highest activity against the most ALL cells are highlighted in black. The colour scale
represents the percentage of NK cells expressing either CD107a or TNFa.
ª 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
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Figure 3. NK cells predominately recognise T-ALL through NKG2D and B-ALL through 2B4. (a) mRNA expression of known ligands of the
activating receptors NKG2D and DNAM-1 on the panel of leukaemic cell targets. (b) Resting PBMCs from the top donors (n = 5–7) against each
leukaemic cell were pre-incubated with either 10 lg mL1 isotype control or 10 lg mL1 anti-NKG2D or anti-DNAM-1 prior to incubation with
each leukaemic cell target for 5 h. After incubation, CD107a expression (top panel) and TNFa production (bottom panel) were measured on
CD56+ CD3- NK cells. Bars represent the means  SEM. PBMCs blocked with anti-NKG2D or anti-DNAM-1 were compared against the isotype
control using the paired Student’s t-test, *P ≤ 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. (c) Surface expression of MICA/B, CD112
and CD155 (measured as MFI) was determined by flow cytometry. (d) Resting PBMCs from the top donors (n = 5 or 6) against each B-ALL cell
were pre-incubated with either 10 lg mL1 isotype control or 10 lg mL1 anti-2B4 prior to incubation with each leukaemic cell target for 5 h.
After incubation, CD107a expression (left panel) and TNFa production (right panel) were measured on CD56+ CD3- NK cells. Bars represent the
means  SEM. PBMCs blocked with anti-2B4 were compared against the isotype control using the paired Student’s t-test, *P ≤ 0.05 and
**P < 0.01.
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These CD57+ NK cells expressed either no KIR or a
single dominant KIR. Despite a strong trend
towards CD57+ NK cells being highly functional,
NK cells co-expressing CD57 were not universally
strong effectors as there were subsets co-
expressing CD57 with poor effector function.
Distinct NK cell subsets dominate across
both B- and T-ALL regardless of HLA
expression
While CD57+ NK cells dominated against both B-
and T-ALL, the range of responses for many of the
subsets varied greatly. To gain a better
understanding into these varied responses, we
next focused our analysis on individual donors
and their responses against each of the ALL cells.
We first selected two superior donors, PB014 and
PB012 with differing target efficacies: PB014 had
a higher propensity for B-ALL compared to T-ALL,
whereas the opposite was true for PB012.
Interestingly, we observed that distinct subsets
dominated across all ALL cells and differed
between the two donors (Figure 5). Despite being
both CMV+, only PB014 relied on adaptive NK
cells expressing NKG2C and CD57 as their most
Figure 4. CD57-expressing NK cell subsets dominate against both B- and T-ALL cells regardless of ALL HLA expression. Each donor was ranked
based on the percentage of CD56+ TNFa+ and CD56+ CD107a+ NK cells against each ALL cell. The top 20 donors were identified, and the CD56+
NK cells expressing CD107a were further subdivided into distinct NK cell subsets based on CD158a, CD158b, KIR3DL1, NKG2C and CD57 staining.
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effective subset, with this subset also expressing
CD158b, while for PB012, NK cells expressing CD57
and CD158a were the most effective.
Surprisingly, despite the leukaemic cells
expressing different combinations of inhibitory
KIR ligands (Table 1) this had little effect on the
subsets with the greatest effector function.
Rather, the same subsets dominated even if the
leukaemic cells were expected to express an HLA
that would be predicted to inhibit the function of
these NK cells. Of particular note, 6/9 ALL cells
expressed KIR ligand C1, and 7/9 ALL cells
expressed KIR ligand C2 (Table 1), yet CD158b+ NK
cells dominated for PB014 and CD158a+
dominated for PB012. Upon analysis of additional
donors with both high responses against B- and T-
ALL cells, we observed the same pattern of
distinct subsets dominating across all ALL cells
regardless of the HLA expressed by the ALL cell
(Supplementary figure 4 and data not shown).
Self-KIR-expressing NK cells are effective in
the presence of their cognate ligand
The observation that distinct NK cell subsets
dominate across our ALL panel irrespective of NK
inhibitory ligand expression is highly relevant for
selecting appropriate donors for NK cell adoptive
therapy. For most clinical trials, these donors are
selected using KIR ligand mismatch models, which
predicts a donor’s response based on the presence
or absence of KIR ligands on the leukaemic cells.
Here, we can show that amongst our top donors
there are clearly highly effective NK cell responses
Figure 5. Distinct NK cell subsets exhibit ALL recognition activity from PB014 and PB012. CD56+ NK cells expressing CD107a or producing TNFa
were further subdivided into distinct NK cell subsets based on CD158a, CD158b, KIR3DL1, NKG2C and CD57 staining. The scale represents the
degree to which each subset (individual squares) contributes to the CD107a+ or TNFa+ population of NK cells.
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in the presence of their cognate ligand. ALL cells
are well known for their high expression of class I
HLA26,27 so the dominance of NK cells in the
presence of their cognate ligand was unexpected.
Analysis of microarray data on these cells
confirmed that all ALL cells in our panel had
similar mRNA expression of class I HLA (Figure 6a).
While cell surface density of pan-HLA class I
(Figure 6b) of each cell varied, all cell lines
expressed at least 9-fold higher levels of HLA class
I compared to the class I-negative cell line K562.
Since we had observed these discordant responses
for our top donors, we broadened our analysis to
all donors to determine whether discordant
responses were seen for the whole cohort. Self-
KIR-expressing cells from each donor were divided
into 6 subsets based on CD158a, CD158b and
KIR3DL1 expression and the presence of their
cognate ligand in their donor (Figure 6c). For PER-
377, CEM and PER-255, self-KIR-expressing NK cells
were predicted to be the most effective (indicated
in green); however, there were still high
discordant responses from some self-KIR-
expressing NK cells failing to meet these
prediction criteria. Similar responses were
observed for TNFa production (data not shown).
This trend was particularly noticeable against the
leukaemic cells expressing the three main
inhibitory ligands, C1 C2 and Bw4 (PER-371,
MOLT-4 and PER-117) with high responses from
NK cells expressing self-KIR in the presence of
their cognate ligand. Interestingly, when HLA
class I was blocked with a pan-HLA class I
antibody, overall NK cell function was increased,
and the same subsets dominated (Supplementary
figure 5 and data not shown) suggesting that
while the ALL cells in our panel express levels of
HLA class I capable of inhibiting NK cell function,
NK cells from our top donors have the capacity to
overcome this inhibition.
In vitro screen identifies the top donors for
adoptive NK cell therapy
Our in vitro screen has clearly identified potential
donors, with highly potent NK cells, that would
have been excluded based on the current
prediction models.9,28 We next evaluated the
capacity of NK cells from these donors to treat
leukaemia in vivo. Donors PB014 (CMV+) and
PB012 (CMV+) were selected as the top donors
against B-ALL PER-371 and T-ALL Jurkat,
respectively. We also selected two donors PB008
(CMVneg) and PB002 (CMVneg) with moderate anti-
tumor efficacy against the chosen ALL cells. NSG
mice were inoculated with either PER-371
(Figure 7a) or Jurkat (Figure 7b) leukaemic cells
followed by adoptive transfer of activated NK
cells. For PER-371, adoptive transfer of NK cells
from PB014 significantly increased survival
compared to no treatment with one mouse
surviving for over 100 days (Figure 7c top panel).
Similarly, mice with T-ALL treated with adoptive
transfer of NK cells from PB012 lived significantly
longer than untreated mice (Figure 7c bottom
panel). More importantly, both our top donors
were better at controlling leukaemia progression
than NK cells from our moderate donors,
providing proof-of-principal evidence that our
in vitro screen can identify optimal donors for NK
cell-based cellular therapies.
DISCUSSION
NK cells are critical mediators of the elimination
of leukaemic cells making them ideal candidates
for cellular therapy. Characteristics of superior
donors or NK cell subset(s) for adoptive NK cell
therapy, however, are poorly understood. Here,
we demonstrate in a population of 49 healthy
donors, there is a potential pool of donors with
superior responses against paediatric ALL, which
could represent a source of effective, functional
NK cells for cellular therapy. These donors
harboured individually distinct NK cell subsets
that were effective against all ALL cells regardless
of the HLA expressed on the leukaemic cells or
the way they recognised each type of ALL.
Collectively, our data highlight the importance of
in vitro functional testing of potential donors.
Many of the superior donors we identified may
not have been selected using currently employed
KIR ligand mismatch selection methods.
Understanding why some donors harbour NK
cells with superior responses against paediatric
ALL remains to be further explored. Based on the
association between CMV reactivation and
leukaemic relapse20 and the enhanced effector
function of NK cells from CMV+ donors,12–16 there
has been a recent interest to develop cellular
therapies from these NK cells.23,24 Liu and
colleagues demonstrated that expanded activated
adaptive NK cells from CMV+ donors efficiently
eliminate HLA-mismatched ALL blasts.24 Here, we
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confirm that adaptive NK cells from CMV+ donors
can recognise ALL, but that these NK cells have a
higher propensity for B-ALL over T-ALL.
Furthermore, while the majority of top donors
were CMV+, there were clearly highly effective NK
cells from CMVneg donors. CMV has been shown
Figure 6. Self-KIR-expressing NK cells are effective in the presence of their cognate ligand. Expression of HLA class I was determined by mRNA
(a) or surface expression (b) measured as MFI using flow cytometry. (c) Self-KIR-expressing NK cells from each donor (n = 49) were divided into
6 subsets based on CD158a, CD158b and KIR3DL1 expression and the presence of their cognate ligand in their respective donor. KIR subsets
predicted to respond in the absence of their cognate ligand on the ALL cell are marked in green.
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to expand subsets of NK cells that have
undergone profound epigenetic reprogramming
resulting in NK cells that can respond more
efficiently.16,19,29 Whether similar changes occur in
our superior CMVneg donors as a result of
exposure to other pathogens or other
environmental exposures remains unclear.
Furthermore, it is not clear whether past exposure
to CMV is the main mechanism in driving
heightened effector responses against paediatric
ALL in our superior CMV+ donors. Nevertheless,
our data clearly demonstrate that effective NK
cells can be identified from both CMV+ and
CMVneg donors and future studies to understand
the mechanisms that drive these superior NK cell
responses are warranted for the design of optimal
adoptive NK cell therapeutic products.
Here, we show that NK cells expressing only
CD57 or co-expressing CD57 were the most
effective. NK cells acquire CD57 as they
functionally mature, and CD57 defines NK cells
that are highly differentiated.18 High frequencies
Figure 7. Adoptive transfer of NK cells improves survival of both B-ALL and T-ALL. NSG mice were irradiated with 250cGy followed by tail vein
injection of either 1 9 106 PER-371 B-ALL (a) or Jurkat T-ALL (b). Mice were either left untreated or treated with 14-day-activated NK cells,
followed by twice-weekly injections of IL-2. (c) Kaplan–Meier curves summarise the survival of mice treated. A total of 6–8 animals were used per
group, and each experiment was performed independently two times. Groups without treatment were compared with treatment groups using
the log-rank (Mantel–Cox) test, *P ≤ 0.05 and ***P < 0.001.
ª 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
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of CD57+ NK cells have been associated with
reduced relapse rates and overall improved
survival in a range of different cancers including
leukaemia.30 However, not all NK cells that
expressed CD57 had heightened responses against
ALL in our panel, and thus, CD57 expression alone
is not sufficient to predict superior donors. While
it is not surprising that CD57 NK cells lacking
expression of the three major inhibitory KIRs
(CD158a, CD158b and KIR3DL1) were the most
effective subsets in the majority of donors, the
high responses from KIR-expressing NK cell subsets
in the presence of their cognate inhibitory ligand
were surprising. In addition, despite the ALL cells
in our panel expressing different combinations of
the three HLA class I KIR ligands C1, C2 and Bw4,
the same NK cell subsets from each individual
donor dominated across all of the ALL cells. It is
possible that a proportion of these NK cells may
express activating KIR which when bound to their
cognate ligand (HLA-C) activates these particular
NK cells. While we did not perform an exhaustive
analysis of activating KIR, our data so far suggest
that at least against the T-ALL Jurkat, activating
KIRs are not the main receptors involved in the
recognition of leukaemia (data not shown).
Collectively, these findings contrast with the
currently used method to select potential donors
in the clinic, which uses the prediction of whether
a potential donor’s NK cells will be inhibited by
the HLA expressed on the leukaemic cell. Relying
on this prediction, we would have failed to
identify the most efficacious donors analysed in
this study. It is possible that the level of HLA class
I required for sufficient inhibition differs amongst
different leukaemic cells. This may result in the
capacity for some subsets of NK cells to mount an
effective response even in the presence of their
cognate inhibitory ligand. These findings also
raise the possibility that strong activating signals
may be overriding inhibitory signals on these NK
cells, allowing the NK cell to eliminate the target
as we and others have previously reported.9,31,32
Collectively, based on our data we would argue
that different subsets may be more effective from
different donors and there is not an overall subset
that is necessarily more effective over another.
Determining the optimal way to identify superior
donors, and their relevant effective subsets, is
certainly warranted to develop improved NK cell
therapies for ALL.
While we observed that distinct subsets of NK
cells show efficacy against all ALL cells, the
mechanism of recognition of B- versus T-ALL
varied greatly. Despite previous reports observing
a role for DNAM-1 in recognition of ALL,25,33
DNAM-1 was only involved in the recognition of
the T-ALL, PER-117. This recognition is likely
driven by the high expression of CD155 on PER-
117, which was expressed at lower levels on all
other cells. Furthermore, in contrast to a previous
study by Toreli and colleagues29 who reported a
role for CD112 in the recognition of paediatric
ALL, despite expression of CD112 on nearly ALL
cells it does not appear that DNAM-1 recognition
of CD112 is involved in enhanced NK cell effector
function against our panel of ALL cells. NKG2D,
however, was the predominant receptor involved
in the recognition of T-ALL. In contrast, NKG2D
was only partially involved in the recognition of
B-ALL in our panel. Despite testing multiple other
receptors, only the SLAM family member 2B4 was
identified as being involved in the recognition of
B-ALL, which was observed for two of the B-ALL
cells despite high surface expression of CD48 also
on PER-377. These two B-ALLs (PER-371 and PER-
278) were the most closely related leukaemias
based on our microarray data,34 raising the
possibility that 2B4 is involved in the recognition
of a subset of B cell leukaemias. In addition, we
cannot conclude why superior NK cells responded
better than other NK cells in recognising ALL. We
performed additional phenotyping to see whether
we could detect a difference between superior
and non-superior donors in respect to expression
of NKG2D, 2B4 or DNAM-1 yet we found no
significant differences between the groups (data
not shown). Our results suggest that NK cell
recognition of paediatric ALL is far more
heterogeneous than previously thought, and
identification of the crucial receptors and
pathways involved will greatly improve the
selection of efficacious NK cells to treat B- and T-
ALL.
While treatment success rates for paediatric ALL
have risen dramatically, children diagnosed with
poor prognosis ALL and patients with relapsed
ALL urgently require improved treatment options.
Cellular therapies derived from the NK cells of
healthy donors provide alternative immune-based
options for these patients. Using our in vitro
screen, we have identified a pool of superior
donors that can be used to develop ‘off the shelf’
cellular therapies to treat these patients. Adoptive
transfer of these superior NK cells significantly
prolonged the survival of mice with either B- or T-
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ALL. While these NK cells alone were not curative,
there are multiple approaches that can be
explored to further enhance the ability of these
superior NK cells to improve the control of
leukaemia. Enriching for particular subsets, such
as CD57+ NK cells, is one approach to improve
therapeutic efficacy. Although CD57+ NK cells are
typically less proliferative compared to CD57neg,
Cichocki and colleagues have demonstrated that
the addition of the small molecule GSK3 inhibitor,
CHIR99021, aids in the enrichment of CD57+ NK
cells.23 Another approach may involve
incorporating chimeric antigen receptors (CAR)
into the most effective NK cells.35 Whether this
involves a CD19 CAR similar to that in use for CAR
T-cell therapy,35,36 a CD5 CAR for T-ALL37 or a CAR
that utilises NK cell activating receptors,38
advancements in our ability to engineer NK cells
have greatly improved the potential to further
enhance NK cells for adoptive cell therapy.
Regardless of which approach or combination of
approaches is selected for further development of
an NK cell-based cellular therapy product, it is
critical that donors with the most effective NK
cells are selected. We have identified superior NK
cells against both B- and T-ALL. Future studies to
understand the mechanisms that drive the
enhanced effector function of these superior NK
cells against not just ALL but other leukaemias
and potentially solid tumors will lead to the
design of robust cellular therapy protocols that
maximise the potential of these superior NK cells
to efficiently eliminate cancer.
METHODS
Donors
Blood was obtained from 49 blood donors attending The
Australian Red Cross Blood Service, Western Australia, with
informed consent obtained in accordance with the
Declaration of Helsinki. Written approval to use blood
samples was obtained from the University of Western
Australia (RA/4/1/7311). Peripheral blood mononuclear cells
(PBMCs) were purified by density centrifugation using
Lymphoprep (StemCell Technologies, Vancouver, Canada)
and cryopreserved. Before analysis for degranulation or
production of intracellular cytokines, the thawed cells were
incubated overnight at 37°C in complete media (R10)
without exogenous cytokines [RPMI (Life Technologies,
Scoresby, Australia) supplemented with 10% foetal calf
serum (Sigma, Castle Hill, Australia), 100 U mL1 penicillin,
100 lg mL1 streptomycin, 2 mM GlutaMax, 24 lM 2-ME, 1%
sodium pyruvate and 1% non-essential amino acids (all Life
Technologies)]. HLA class I typing was performed for each
donor by next generation sequencing of exons 2 and 3 of
HLA-A, HLA-B and HLA-C by the Institute of Immunology
and Infectious Diseases, Murdoch University, Australia.
Cell lines
Patient-derived cell lines PER-371, PER-377, PER-145, PER-
278, PER-255 and PER-117 were established from the bone
marrow of paediatric patients being treated at the former
Princess Margaret Hospital for Children in Perth, Australia
(Table 1), as previously reported.34 Commercial cell lines
JURKAT, MOLT-4, CEM and the class I-negative cell line
K562 were obtained from the American Type Tissue Culture
(ATCC) (Manassas, VA). All cell lines were cultured in R10
and used in experiments within three weeks after thawing.
Each cell line was determined to be mycoplasma free using
the MycoAlert Mycoplasma Detection Kit (Lonza, Basel,
Switzerland). The ALL cells used in this study have been
previously analysed on a cDNA microarray measuring 13,286
human cDNAs.34 Data relevant to this project were
extracted from this published data set. HLA class I typing of
each ALL cell was performed by next generation
sequencing of exons 2 and 3 of HLA-A, HLA-B and HLA-C.
Surface HLA class I expression was determined by flow
cytometry using unconjugated anti-HLA-A,B,C (W6/32;
BioLegend, San Diego, CA) followed by staining with Alexa
Fluor 647-conjugated rat anti-mouse IgG2a (BioLegend).
Surface expression of NK ligands was determined using
MICA/B (6D4), CD112 (TX31), CD155 (SKII.4) and CD48 (BJ40)
antibodies (all BioLegend). Cells were analysed on a BD LSR
Fortessa (BD Biosciences, San Jose, CA) and median
fluorescence intensity (MFI) calculated using FlowJo Version
10 software (TreeStar, Ashland, OR).
Determination of CMV status
Cytomegalovirus serostatus was determined by testing
performed by the Australian Red Cross Blood Service where
possible. For donors where the CMV serostatus was
unknown, PBMCs were stimulated with PepMix HCMVA
(pp65) (JPT Peptide Technologies, Berlin, Germany)
overnight before CMV-specific T cells were determined
using an IFNc ELISPOT as previously described.39,40
Functional flow assay
Expression of CD107a and production of TNFa were
measured as described previously.41 Briefly, PBMCs were
incubated with B-ALL, T-ALL or K562 target cells at an
effector-to-target ratio of 2:1 for 5 h. For some
experiments, PBMCs were pre-incubated with either
10 lg mL1 of isotype control or 10 lg mL1 of anti-HLA-A,
B,C, anti-HLA-E (3D12), anti-NKG2D (1D11), anti-DNAM-1
(11A8), anti-NKp30 (P30-15), anti-NKp46 (9E2) and anti-2B4
(C1.7) (all BioLegend), for 20 min at 37°C. Brefeldin A and
monensin (both BD Biosciences) were added after 1 h. The
following antibodies were used: anti-NKG2C (134591; R&D
Systems, Minneapolis, MN), anti-KIR3DL1 (DX9; BioLegend),
anti-CD56 (clone B159), anti-CD3 (SK7), anti-CD57 (NK-1),
anti-CD158a (HP-3E4), anti-CD158b (CH-L), anti-CD107a
(H4A3), anti-TNFa (MAb11) and fixable viability stain FV575
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(all BD Biosciences). Cells were analysed on an BD LSR
Fortessa and using FlowJo Version 10 software.
NK cell expansion
CD3+ cells were depleted from each donor’s PBMC using
CD3+ magnetic bead selection (StemCell Technologies) prior
to expansion with irradiated K562 cells at a 6:1 ratio in R10
supplemented with 10 IU mL1 (increasing to 100 IU mL1
on day 7) recombinant human IL-2 (Life Technologies) and
5 ng mL1 recombinant human IL-15 (PeproTech, Rocky Hill,
NJ), replacing half the media every 2–3 days and splitting
1:4 on day 7. On day 14, cells were counted and washed
three times in PBS in preparation for adoptive transfer.
In vivo adoptive transfer
Eight- to ten-week-old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
(NSG) mice were purchased from the Animal Research
Centre, Perth, Australia. Animals were housed under
specific pathogen-free conditions, and all studies were
approved by the Animal Ethics Committee, Telethon Kids
Institute, Perth, Australia. Mice received one dose of 250cGy
irradiation followed by transfer of 1 9 106 PER-371 or
Jurkat cells. Following engraftment of leukaemic cells, mice
received adoptive transfer of 2.5 9 106 activated NK cells.
Mice received twice-weekly (for 2–3 weeks as indicated)
5 lg injections of recombinant human IL-2 (Life
Technologies). Mice were monitored for disease
progression, and once symptoms of leukaemia developed,
mice were euthanised. Bone marrow, spleen and blood
were analysed by flow cytometry for the presence of
leukaemic cells.
Statistics
Data were summarised with mean and standard error of
the mean (mean  SEM). For comparisons between
independent samples, the Student’s t-test was used. For
comparisons of matched samples, the paired t-test was
used. For in vivo experiments, length of survival between
groups was compared using the log-rank (Mantel–Cox) test.
Statistical significance was indicated as *P ≤ 0.05,
**P < 0.01, ***P < 0.001 and ****P < 0.0001. Statistical
analyses were performed using Prism 7 (GraphPad Software,
San Diego, CA, USA).
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